Современная ревматология (Sep 2019)

Experience with canakinumab in a patient with gout and IgA nephropathy

  • E. V. Ilyinykh,
  • M. S. Eliseev

DOI
https://doi.org/10.14412/1996-7012-2019-3-71-75
Journal volume & issue
Vol. 13, no. 3
pp. 71 – 75

Abstract

Read online

The paper discusses the results of clinically using the interleukin-1_ inhibitor canakinumab in a patient with chronic tophaceous gout, IgA nephropathy, and chronic kidney disease with resistance to traditional anti-inflammatory drugs (colchicine, nonsteroidal anti-inflammatory drugs (NSAIDs), and high-dose glucocorticoids) and a history of failed urate-lowering therapy. It demonstrates the possibility of safely using subcutaneous canakinumab 150 mg that is superior to therapy with high-dose prednisone (40-80 mg/day) and NSAIDs. Canakinumab has also reduced the risk of exacerbations of arthritis when choosing urate-lowering therapy.

Keywords